Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Can't really see a purchase yet, Dil. Still think it'll take time to get all the skeletons out - usually does.

However, there'll be time to go long eventually

;-0

RNS Number:4690N
BioProgress PLC
13 June 2005


Press Release 13 June 2005




BioProgress plc


("BioProgress" or "the Company")

Peter Glynn-Jones



The Board of BioProgress plc (AIM: BPRG; NASDAQ: BPRG) regrets to announce the
sudden death of Peter Glynn-Jones, Non-Executive Chairman of the Company
aged 58.



Peter joined the Board as a Non-Executive Chairman in May 2003. He was formerly
a senior executive of SmithKline Beecham Plc, now GlaxoSmithKline Plc, and a
non-executive director of Peter Black Plc until it was taken private.



Speaking on behalf of the Board and employees of BioProgress Plc, Richard
Trevillion, Chief Executive, said:



"We are deeply saddened to learn of Peter's death. As Chairman since 2003 he
played an important role in the growth of the Company. He will be greatly
missed and our thoughts are with his family."



An announcement in relation to a successor to Peter Glynn-Jones will be made in
due course.

interesting chart

What do the wise men say about the SP movement to-day. Smallish Volume B/s 54/45 larger sized buys than sells, but SP down by 3.5%. Is there a large protected sale going through. I would have read the recent announcement as fair and reasonable. But ?????

Still 22p target Fred ... sorry.

me singing to Dil:
`it ain`t necessarily so` de dum de dum

short term chart I know but it`s sometimes that kind of stock

macd showing positivity

Dil I don't think it will dive to 22p but 29-30p is possible, but I think from looking at the indicators and this miserable chart the sp will be up over the next few days and weeks.

Dil
Have you not seen the news and specculation over on ADVFN
FMC and Bioprogress partnership and news did not come out until after mkt hrs on Friday so it will be a level playing field at open


FMC BioPolymer Announces New Name for Oral Dose Technology Unit
PHILADELPHIA, June 21, 2005 - FMC BioPolymer, today announced a new identity for its business unit focused on oral dose technologies. The unit, to be called Magenta Oral Dose Design, is currently developing the NRobe system for powder enrobing, and several alternatives to soft capsule dose forms. FMC BioPolymer is a division of FMC Corporation (NYSE: FMC).
"As we interact more strongly with prospective customers and publish more information, it makes sense for us to have a distinctive and recognizable name and identity." commented Robin Mitchell, Director, New Pharmaceutical Business. "We chose Magenta because it reflects our core values, is ownable and has great potential as a point of difference. Of course, it is the strength and value of our technologies that will really define our presence in the market via the business opportunities they create for us, our partners and our customers. We continue to make good progress towards commercialization of our technologies." More details, including a website, will be made available shortly

Looks good for monday me think.

Link for information

http://www.bioprogress.com/html/news/archive/09-11-04.html

http://www.fmcbiopolymer.com/Biopolymer/V2/BIONewsDetail/0,1418,3010,00.html


Looks promising.

BioProgress PLC
27 June 2005

SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES


1. Name of company

Bioprogress plc

2. Name of shareholder having a major interest
FMC and it's direct and indirect subsidiaries and
Fidelity International Limited and it's direct and indirect subsidiaries

3. Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18.

As above

4. Name of the registered holder(s) and, if more than one holder, the number
of shares held by each of them

172,688 Brown Brothers Harriman Lux
3,946,901 Mellon Bank N.A.

5. Number of shares/amount of stock acquired

Not disclosed

6. Percentage of issued class

Not disclosed

7. Number of shares/amount of stock disposed

831,099

8. Percentage of issued class

Not disclosed

9. Class of security

Ordinary shares of 1p each

10. Date of transaction

Not disclosed

11. Date company informed

27 June 2005

12. Total holding following this notification

4,118,901

13. Total percentage holding of issued class following this notification

3.38%

14. Any additional information

15. Name of contact and telephone number for queries

Georgina Godby, 01354 602186

16. Name and signature of authorised company official responsible for making
this notification.

Georgina Godby, Company Secretary

Date of notification: 27 June 2005





I would have thought this was done a couple of days ago as it hasn't been marked up to-day or effected the price.



***************************
How long is it before they have to notify a deal of this size?

******************************************

When is this company going to announce something which is going to make it money?

Probably the day I decide to sell out of it

ill be selling on the same day as you then, lol. and if we stay in, it'll never go up, you cant win.

BioProgress PLC
29 July 2005


BioProgress plc
('BioProgress' or 'the Company')

Appointment of Chairman

The Board of BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of
innovative delivery mechanisms for the pharmaceutical oral dosage markets, is
pleased to announce the appointment of Peter Ibbetson as non executive Chairman
with immediate effect.

Peter Ibbetson, aged 49, is an experienced banker and non-executive director
with an extensive background in Corporate, Investment, and Retail banking. From
1974 to 2003 he was employed in the NatWest and RBS Group where he was most
recently Director of Investment Banking / Head of Aerospace, and Head of
Business Banking. He is a member of the Government's Small Business Investment
Taskforce which looks at venture capital and Equity Gap funding. He is
currently is a director of Utilyx Limited, the Local Investment Fund and Drayton
Building Services Limited. He is also Regional Chairman for East Anglia of
Coutts and Co, and Chairman of The Princes Trust for Cambridgeshire.

He will be a member of the Audit Committee and of the Remuneration Committee.


Richard Trevillion BioProgress Chief Executive said:

'We are delighted that Peter has agreed to join our Board. We are fortunate to
have attracted an individual with the calibre, business skills and contacts
Peter brings to our team. I am looking forward to working more closely with him
in the further development of the Company.

'We plan to continue to strengthen the Board over the next few months following
our strategic review earlier this year.'


Peter Ibbetson said:

'I have the highest regard for the new management team and look forward to
working with Richard and Dan at this very exciting stage of the Group's
development.'

Peter Ibbetson was a Director over the past five years of RBS Commercial
Services Limited and RBS Pension Trustees Limited. No further disclosures are
required to be made in relation to Peter Ibbetson under Schedule Two paragraph
(g) of the AIM Rules.


29 July 2005

Enquiries:

BioProgress plc 01354 655674
Richard Trevillion, Chief Executive Officer
Dan Farrow, Finance Director

College Hill 020 7457 2020
Adrian Duffield/Corinna Dorward

Last post 29th July.

Is it worth the bovver.

Rayrac

Breakout, time to bury the hatchet and get back in.

Sad git.

As long as they have a certain shareholder on the list I will not touch it!

Not you is it bloodhound? Only you do seem to have a large holders memory! :)

Does look a better bet though (at last))

Breakout my ar*e !

LOL! But I get your point Dil. Breakout driven by what? Expectation? Nothing in sight so far!

Down Dil. Patience will show, but it may take a lot of patience.